Omicron: Merck says its Covid-19 anti-viral pill will have similar efficacy against Omicron
|US pharmaceutical giant Merck said on Tuesday that it expected its antiviral pill to show similar activity against any new Covid-19 variant, including Omicron, according to Reuters. The company's remarks come after the Regeneron CEO said live on CNBC earlier in the session that he thought Merck's pill would no longer work.
Market Reaction
Markets do not seem to have reacted to the latest headlines much. Merck's pill does not yet form an important part of the global prevention/Covid-19 treatment regime. Markets are more sensitive right now to headlines about vaccine efficacy, the transmissibility of Omicron and the severity of illness when infect by the new variant.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.